Industry News


Danger Zone: Highlights And Lowlights Of 2016

8h seekingalpha
Our Danger Zone reports aim to identify those firms that, when looking below the surface, have struggling businesses and highly overvalued stock prices.

International Business Machines' (IBM) Management on Q4 2016 Results - Earnings Call Transcript

8h seekingalpha
Welcome and thank you for standing by. At this time, all participants are in a listen-only mode. Today’s conference is being recorded. If you have any objections you may disconnect at this time.

Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

9h zacks
Mallinckrodt plc (MNK - Free Report) , will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter’s investigation into the acquisition of Synacthen Depot by its Questcor division. Synacthen Depot, is a synthetic adrenocorticotropic hormone (ACTH) drug.

Surgery Partners a longer-horizon acquisition target says TheStreet's Pringle

11h seekingalpha
TheStreet's Sarah Pringle reports that UnitedHealth Group's (UNH +1.1%) recent $2.3B takeout of Surgical Care Affiliates (SCAI) bodes well for competitor Surgery Partners (SGRY -2.2%) which debuted in September 2015.

Community Health Systems: Should We Bet On This Deleveraging?

11h seekingalpha
Shares of Community Health Systems have crashed as a result of concerns about the company's excessive leverage.

CRUCIAL EQUITY ALERT: Lundin Law PC Announces an Investigation of Universal Health Services, Inc. and Advises Investors with Losses to Contact the Firm

12h accesswire
LOS ANGELES, CA / ACCESSWIRE / January 19, 2017 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Universal Health Services, Inc. ("UHS" or the "Company") (NYSE: UHS) concerning possible violations of federal securities laws.

Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards

12h marketwired
WASHINGTON, DC--(Marketwired - Jan 19, 2017) - The international Standards Coordinating Body for regenerative medicines (SCB), in coordination with the Alliance for Regenerative Medicine (ARM), today announced its formal launch as a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and gene-modified cell therapy, cell therapy, cell-based drug discovery, tissue engineering and biomaterials sectors.

The Alliance for Regenerative Medicine Launches Standards Coordinating Body to Advance Development and Establishment of Industry-Wide Standards

14h marketwired
WASHINGTON, DC--(Marketwired - Jan 19, 2017) -   The Alliance for Regenerative Medicine (ARM) today announced the formal launch of the international Standards Coordinating Body for regenerative medicines (SCB), a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and gene-modified cell therapy, cell therapy, cell-based drug discovery, tissue engineering and biomaterials sectors.

Here's Why Teladoc Soared Nearly 14% Higher This Morning

16h fool
Shares of on-demand healthcare provider Teladoc (NYSE:TDOC) rose as much as 13.9% Thursday in the first two hours of trading after the company announced that it would price up to 9,487,500 shares of common stock, including underwriter options for additional equity, at $16.75 per share. If fully subscribed, the offering will bring in $159 million in gross proceeds.

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Universal Health Services, Inc. and Advises Investors with Losses to Contact the Firm

17h accesswire
LOS ANGELES, CA / ACCESSWIRE / January 19, 2017 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Universal Health Services, Inc. ("UHS" or the "Company") (NYSE: UHS) concerning possible violations of federal securities laws.

Varian Medical (VAR) Q1 Earnings: Is a Surprise in Store?

17h zacks
Varian Medical Systems Inc. (VAR - Free Report) is set to report results for the first quarter of fiscal 2017 on Jan 25, after the closing bell. Last quarter, the company reported earnings of $1.38 per share, which beat the Zacks Consensus Estimate by three cents. Notably, the figure improved 32.7% on a year-over-year basis. We note that on average, Varian Medical posted a positive earnings surprise of 3.

Liquid Biopsy Market is Predicted to Grow at a CAGR of 21.6% from 2016 to 2022

18h prnewswire
PUNE, India, Jan. 19, 2017 /PRNewswire/ -- Market Research Future has a half cooked research report on Global Liquid Biopsy Market. The Global Market for Liquid Biopsy is growing rapidly and expected to reach USD 450 Million by the end of the forecasted period.

IDEXX Laboratories (IDXX) Q4 Earnings: What's in Store?

18h zacks
IDEXX Laboratories, Inc. (IDXX - Free Report) is slated to report fourth-quarter 2016 results on Feb 2, before the opening bell.

Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

18h zacks
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Danger Zone: Highlights & Lowlights Of 2016

19h seekingalpha
Our Danger Zone reports aim to identify those firms that, when looking below the surface, have struggling businesses and highly overvalued stock prices.

Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?

19h zacks
Boston Scientific Corporation (BSX - Free Report) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2. Last quarter, the company’s earnings were in line with the Zacks Consensus Estimate. It posted an average beat of 5.17% in the trailing four quarters. Let’s see how things are shaping up prior to this announcement.

Neuralstem completes round trip

21h seekingalpha
Thinly traded nano cap Neuralstem (CUR -1.8%) provides the latest example of the dangers of chasing "big pops" in biotech. The stock has completely retraced its 59% move on January 10 stoked by the issuance of a new patent covering its stem cells. Shares are currently exchanging hands at ~$3.79, slightly below the close of $3.81 on January 9.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $250,000 Investing In Universal Health Services, Inc. To Contact The Firm Before Lead Plaintiff Deadline

2017-01-19 prnewswire
NEW YORK, Jan. 19, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Universal Health Services, Inc. ("Universal Health" or the "Company") (NYSE: UHS) of the February 21, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The Strategic Impact Of UnitedHealth's Latest Acquisition

2017-01-19 seekingalpha
The deal will strategically work to deepen its presence in the sphere of ambulatory, outpatient healthcare services, particularly as a low-cost provider where there is growing demand.

Allergan's Uterine Fibroids Candidate Positive in Phase III

2017-01-18 zacks
Allergan Plc (AGN - Free Report) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, a selective progesterone receptor modulator (SPRM), in women with abnormal bleeding due to uterine fibroids.  

5 Signs HCP's Best Days Are Ahead

2017-01-18 fool
Healthcare real estate investment trust HCP, Inc. (NYSE:HCP) underwent a pretty dramatic change in 2016. It started the year with about one-third of its portfolio made up of unstable assets leased to a troubled operator, and ended with a solid portfolio of about 800 high-quality properties. Here are the details of the transformation, and why I think HCP has a bright future ahead.

Concert Offers Update on Cystic Fibrosis Drug, Stock Down

2017-01-18 zacks
Concert Pharmaceuticals, Inc. (CNCE - Free Report) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe. Shares of the company were down approximately 14% on the news.

Teladoc Announces Stock Sale to Finance Growing Business

2017-01-18 zacks
Telehealth provider, Teladoc Inc. (TDOC - Free Report) has announced to sell 5,400,000 shares of its common stock, in an effort to procure funds for expansion. This financing option has been chosen as the company is rapidly expanding its business. The proceeds from the sale of these shares will be used for general corporate purposes, which  include funding for acquisitions and investments in other business, products and technologies.

Quest Diagnostics Release: Company Launches Nation's First Hepatitis B Virus Quantitative Test To Help Assess Response To Antiviral Therapy

2017-01-18 devicespace
MADISON, N.J., Jan. 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient's response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.

Jazz Begins Phase III Study for Label Expansion of Defitelio

2017-01-18 zacks
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease (VOD) in high-risk adult and pediatric patients. Defitelio is currently available in the U.S. for the treatment of adult and pediatric patients with hepatic VOD with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).